David Kiesl
Overview
Explore the profile of David Kiesl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
90
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Niedersuess-Beke D, Mayrhofer K, Krauter J, Schnabel S, Gampenrieder S, Miechowiecki J, et al.
Clin Genitourin Cancer
. 2024 Dec;
23(1):102278.
PMID: 39672785
Aim: Enfortumab vedotin (EV) represents a novel treatment for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) refractory to platinum-based chemotherapy and PD(L)-1 containing therapies. Real-world data are crucial...
2.
McGowan H, Gutenberg J, Leitner V, Muhlhauser K, Breda A, Fischer M, et al.
PLoS One
. 2024 May;
19(5):e0302226.
PMID: 38753841
Cardiac rehabilitation (CR) patients often do not sustain physical activity (PA) behaviour in the long run, once they progress into a self-management stage of secondary prevention. This study aimed to...
3.
McGowan H, Gutenberg J, Leitner V, Muhlhauser K, Breda A, Fischer M, et al.
Digit Health
. 2023 Dec;
9:20552076231219437.
PMID: 38089166
Objective: Digital health technologies offer great potential to improve access and adherence to cardiovascular disease secondary prevention measures such as regular physical activity (PA). However, the use and perceptions of...
4.
Schlagheck M, Bansi J, Wenzel C, Kuzdas-Sallaberger M, Kiesl D, Gonzenbach R, et al.
Eur J Neurol
. 2023 May;
30(9):2726-2735.
PMID: 37209371
Background And Purpose: Valid measurements of cardiorespiratory fitness in persons with multiple sclerosis (pwMS) are essential during inpatient rehabilitation for a precise evaluation of the current health status, for defining...
5.
Sleurs C, Amidi A, Wu L, Kiesl D, Zimmer P, Lange M, et al.
Crit Rev Oncol Hematol
. 2022 Oct;
180:103859.
PMID: 36257539
Cancer-related cognitive impairment (CRCI) has increasingly been identified over the last two decades in non-CNS system cancer patients. Across Europe, researchers have contributed to this effort by developing preclinical models,...
6.
Leisch M, Pfeilstocker M, Stauder R, Heibl S, Sill H, Girschikofsky M, et al.
Cancers (Basel)
. 2022 May;
14(10).
PMID: 35626063
Azacitidine is the treatment backbone for patients with acute myeloid leukemia, myelodysplastic syndromes and chronic myelomonocytic leukemia who are considered unfit for intensive chemotherapy. Detailed reports on adverse events in...
7.
Kiesl D, Kuzdas-Sallaberger M, Fuchs D, Brunner S, Kommenda R, Tischler C, et al.
Front Neurol
. 2022 Apr;
13:777808.
PMID: 35401389
Introduction: Epidemiological studies show that increased physical activity is linked to a lower risk of breast cancer and mortality. As a result, physical activity can significantly improve patients' quality of...
8.
Kierdorf F, Zimmer P, Joisten N, Kiesl D, Winker M, Rigoux L, et al.
Leuk Lymphoma
. 2022 Mar;
63(8):2001-2004.
PMID: 35357984
No abstract available.
9.
Strasser B, Paar C, Kiesl D, Tomasits J
Lab Med
. 2021 Dec;
53(5):e101-e104.
PMID: 34940837
A male patient with a persistent, combined erythrocytosis, leukocytosis, and thrombocytosis without representative evidence of reactive increase emerged as having a myeloproliferative disorder. Molecular-biological assessment yielded Janus kinase 2-positive results,...
10.
Zimmer P, Hillebrand P, Wolf F, Joisten N, Walzik D, Hardt L, et al.
Leuk Lymphoma
. 2021 Apr;
62(10):2526-2530.
PMID: 33879029
No abstract available.